CANCER:

Cervical Cancer

Related cancers:

‹

›

No biomarker No biomarker	Cervical Cancer Cervical Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Cervical Cancer Cervical Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Cervical Cancer Cervical Cancer	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Cervical Cancer Cervical Cancer	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Cervical Cancer Cervical Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Cervical Cancer Cervical Cancer	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Cervical Cancer Cervical Cancer	paclitaxel + topotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	5-fluorouracil Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	carboplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	vinorelbine tartrate Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	pemetrexed Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	irinotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	gemcitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	topotecan Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Cervical Cancer Cervical Cancer	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Cervical Cancer Cervical Cancer	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Cervical Cancer Cervical Cancer	entrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Cervical Cancer Cervical Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Cervical Cancer Cervical Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Cervical Cancer Cervical Cancer	larotrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	cisplatin Sensitive: A2 - Guideline
TMB-H TMB-H	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	cisplatin + topotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	CaT Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	CPB Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	VC Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	EP Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	CP Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	TPB Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	carboplatin + etoposide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	cisplatin + etoposide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Cervical Cancer Cervical Cancer	AGEN2034 + AGEN1884 Sensitive: B - Late Trials
No biomarker No biomarker	Cervical Cancer Cervical Cancer	AGEN2034 Sensitive: B - Late Trials
No biomarker No biomarker	Cervical Cancer Cervical Cancer	HuMax-TF-ADC Sensitive: B - Late Trials
No biomarker No biomarker	Cervical Cancer Cervical Cancer	pembrolizumab + bevacizumab Sensitive: B - Late Trials
No biomarker No biomarker	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: B - Late Trials
MSI-H/dMMR MSI-H/dMMR	Cervical Cancer Cervical Cancer	nivolumab + ipilimumab Sensitive: C1 - Off-label
HER-2 overexpression HER-2 overexpression	Cervical Cancer Cervical Cancer	trastuzumab Resistant: C1 - Off-label
HER-2 mutation HER-2 mutation	Cervical Cancer Cervical Cancer	neratinib Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	AB122 Sensitive: C2 – Inclusion Criteria
DDR DDR	Cervical Cancer Cervical Cancer	BAY1895344 Sensitive: C2 – Inclusion Criteria
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	HLX10 Sensitive: C2 – Inclusion Criteria
PRDX2 overexpression PRDX2 overexpression	Cervical Cancer Cervical Cancer	cisplatin Resistant: C3 – Early Trials
PRDX1 overexpression PRDX1 overexpression	Cervical Cancer Cervical Cancer	cisplatin Resistant: C3 – Early Trials
AJUBA overexpression AJUBA overexpression	Cervical Cancer Cervical Cancer	cisplatin Resistant: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Cervical Cancer Cervical Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	anlotinib + sintilimab Sensitive: C3 – Early Trials
FGFR3-TACC3 F17T8 FGFR3-TACC3 F17T8	Cervical Cancer Cervical Cancer	ABSK-091 Sensitive: C3 – Early Trials
CXCL8 elevation CXCL8 elevation	Cervical Cancer Cervical Cancer	ipilimumab Resistant: C3 – Early Trials
TNFA elevation TNFA elevation	Cervical Cancer Cervical Cancer	ipilimumab Resistant: C3 – Early Trials
IL6 elevation IL6 elevation	Cervical Cancer Cervical Cancer	ipilimumab Resistant: C3 – Early Trials
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	rivoceranib + camrelizumab Sensitive: C3 – Early Trials
TXN overexpression TXN overexpression	Cervical Cancer Cervical Cancer	cisplatin Resistant: C3 – Early Trials
PD-L1 expression PD-L1 expression	Cervical Cancer Cervical Cancer	pembrolizumab + bevacizumab Sensitive: C3 – Early Trials
BRCA2 exon 11 deletion BRCA2 exon 11 deletion	Cervical Cancer Cervical Cancer	ABSK-091 Sensitive: C4 – Case Studies
BRCA1 mutation + TP53 R248Q BRCA1 mutation + TP53 R248Q	Cervical Cancer Cervical Cancer	bevacizumab + olaparib Sensitive: C4 – Case Studies
BRCA1 positive BRCA1 positive	Cervical Cancer Cervical Cancer	bevacizumab + olaparib Sensitive: C4 – Case Studies
MAPK4 deletion MAPK4 deletion	Cervical Cancer Cervical Cancer	PARP inhibitor Sensitive: D – Preclinical
RAD51 underexpression RAD51 underexpression	Cervical Cancer Cervical Cancer	olaparib Sensitive: D – Preclinical
HUWE1 mutation HUWE1 mutation	Cervical Cancer Cervical Cancer	GS-626510 Sensitive: D – Preclinical
MYC overexpression MYC overexpression	Cervical Cancer Cervical Cancer	GS-626510 Sensitive: D – Preclinical
ROR1 expression ROR1 expression	Cervical Cancer Cervical Cancer	sirolimus Sensitive: D – Preclinical
TROP2 expression TROP2 expression	Cervical Cancer Cervical Cancer	sacituzumab govitecan-hziy Sensitive: D – Preclinical
PIK3CA mutation PIK3CA mutation	Cervical Cancer Cervical Cancer	neratinib + copanlisib Sensitive: D – Preclinical
HER-2 mutation HER-2 mutation	Cervical Cancer Cervical Cancer	afatinib Sensitive: D – Preclinical
NCL overexpression NCL overexpression	Cervical Cancer Cervical Cancer	QN-165 Sensitive: D – Preclinical
TBX1 overexpression TBX1 overexpression	Cervical Cancer Cervical Cancer	cisplatin Sensitive: D – Preclinical
NCL overexpression NCL overexpression	Cervical Cancer Cervical Cancer	cisplatin Resistant: D – Preclinical
DIRAS3 overexpression DIRAS3 overexpression	Cervical Cancer Cervical Cancer	paclitaxel Sensitive: D – Preclinical

Cervical Cancer

Associations(78)

Associations
(78)